Stereotactic ablative radiotherapy (SABR): Impact on the immune system and potential for future therapeutic modulation

Adam S. Reese, Steven J. Feigenberg, Azmat Husain, Tonya J. Webb, Petr F. Hausner, Martin J. Edelman, Josephine Feliciano, Katherine H. Tkaczuk, Navesh K. Sharma

Research output: Contribution to journalArticle

Abstract

Stereotactic ablative radiotherapy (SABR) has been demonstrated to provide excellent local control in several malignancies. Recent reports have suggested that this ablative dose may impact disease outside of the radiated area. Furthermore, these studies have implicated immune modulation as the primary mechanism of disease response outside the irradiated area. More specifically, T-cell stimulation and tumor necrosis factor-αmodulation following high dose irradiation have been suggested as the responsible components of this phenomenon. In addition, the "abscopal effect" may play a role in disease response outside of the radiated area. We review the current literature regarding the effects of ablative radiation therapy, the potential for immune modulation from it, and the mechanisms of the distant effects it elicits.

Original languageEnglish (US)
Pages (from-to)19-25
Number of pages7
JournalMolecular and Cellular Pharmacology
Volume5
Issue number1
DOIs
StatePublished - Jul 19 2013
Externally publishedYes

Keywords

  • Ablative radiotherapy
  • Immune response
  • Therapeutic modulation

ASJC Scopus subject areas

  • Molecular Biology
  • Pharmaceutical Science

Fingerprint Dive into the research topics of 'Stereotactic ablative radiotherapy (SABR): Impact on the immune system and potential for future therapeutic modulation'. Together they form a unique fingerprint.

  • Cite this

    Reese, A. S., Feigenberg, S. J., Husain, A., Webb, T. J., Hausner, P. F., Edelman, M. J., Feliciano, J., Tkaczuk, K. H., & Sharma, N. K. (2013). Stereotactic ablative radiotherapy (SABR): Impact on the immune system and potential for future therapeutic modulation. Molecular and Cellular Pharmacology, 5(1), 19-25. https://doi.org/10.4255/mcpharmacol.13.04